Buradasınız

Anasayfa » Content

A rare case of disseminated strongyloidiasis

Journal Name:

  • Indian Journal of Basic & Applied Medical Research

Publication Year:

  • 2015

Key Words:

Author NameUniversity of Author
Abstract (2. Language): 
Strongyloid stercoralis infection affectshundreds of millions of people world wide,although no precise estimate is available. Although most infected individuals are asymptomatic, it is capable of transforming into a fulminant fatal illness under certain conditions associated with compromise of host immunity. A case of 36 years old immune compromised male with erythematous skin lesions who developed disseminated strongyloidiasis after treatment with steroids. The patient was treated with Ivermectin 200mcg /Kg daily. Patient expiredwith fatal illness inspite of treatment.Conclusion: Proper screening is mandatory in high risk patients and awareness regarding disseminated form of strongyloidiasis for clinicians. Ivermectin is the gold standard treatment.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-rare-case-disseminated-strongyloidiasis.pdf
  • 2
184
188
  • English

REFERENCES

References: 

1.Grove, D. I. 1989. Historical introduction, p. 1-9. In D. I. Grove (ed.), Strongyloidiasis: a major roundworm
infection of man. Taylor & Francis, Philadelphia, Pa.
2. Grove, D. I. 1989. Clinical manifestations, p. 155-173. In D. I. Grove (ed.), Strongyloidiasis: a major roundworm
infection of man. Taylor & Francis, Philadelphia, Pa.
3.WHO:Strongyloidiasis.http://www.who.int/neglected diseases/strongyloidiasis/en/.
4. Rotman HL, Yutanawiboonchai W, Brigandi RA, Leon O, Nolan TJ, Schad GA, et al. Complete life cycle in
SCID mice. Exp Parasitol 1995,81(1):136-139
5. Patil P, Jayshreee RS, Acharya RS, Sridhar H, Babu G, Suresh TM. Fulminant fatal stronglyoides stercoralis
infection in a postchemotherapy immune suppressed cancer patient. Med pediatric Oncol 1999,33 (5):504-505
6. Markis AN, Sher S, Bertiku C, Latour MG. Pulmonary strongyloidiasis: an unusual opportunistic pneumonia in a
patient with AIDS. AJR Am J Roentgenol 1993,161(3):545-547
7. Ghosh K, Ghosh K. Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: report of
three cases. Trans R Soc Trop Med Hyg. 2007 Nov;101(11):1163-5. Epub 2007 Jul 26.
8.Marcos LA, Terashima A, Canales M, Gotuzzo E.Update on strongyloidiasis in the immuno compromised host.
Curr Infect Dis Rep. 2011 Feb;13(1):35-46. doi: 10.1007/s11908-010-0150-z.
9. Keiser PB, Nutman TB. Strongyloids stercoralis in the Immunocompromised Population. Clin Microbiol Rev.
2004 Jan;17(1):208-17.
10.Upadhyay D, Corbridge T, Jain M, Shah R.Pulmonary hyperinfection syndrome with Strongyloides stercoralis.
Am J Med 2001, 111(2): 167-169.
11. Csermely L, Jaafar H, Kristensen J, Castella A, Gorka W, Chebli AA, et al. Strongyloides hyper infection
causing life- threatening gastrointestinal bleeding . World J Gastroenterol. 2006 Oct 21;12(39):6401-4.
12. Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann
Pharmacother 2007;41(12):1992- 2001. Epub 2007 Oct 16.
Indian Journal of Basic and Applied Medical Research; March 2015: Vol.-4, Issue- 2, P. 184-188
185
www.ijbamr.com P ISSN: 2250-284X , E ISSN : 2250-2858
13. Siddiqui AA and Berk SL.Diagnosis of strongyloides steroralis infection. Clin Infect Dis. 2001 Oct
1;33(7):1040-7. Epub 2001 Sep 5.
14. Porto AF, Neva FA, Bittencourt H, Lisboa W, Thompson R, Alcântara L, et al. HTLV -1 decreases Th2 type of
immune response in patients with strongyloidiasis. Parasite Immunol 2001 Sep;23(9):503-7.
15.WHO:Model list of essential medicines.htpp://www.who.int/medicines/publications/essential medicines/en/.
16.Buonfrate D, Requena-Mendez A, Angheben A, Muñoz J, Gobbi F, Van Den Ende J, et al. Severe
strongyloidiasis: a systematic review of case reports. BMC Infect Dis. 2013 Feb 8;13:78. doi: 10.1186/1471-2334-
13-78.

Thank you for copying data from http://www.arastirmax.com